LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Gel and Capillary Electrophoresis Compared for Human Proteins

By LabMedica International staff writers
Posted on 12 May 2021
Print article
Image: The Capillarys 3 TERA is an automated analyzer based on capillary zone electrophoresis and UV detection for the quantitative analysis of Hba1c, proteins (serum and urine), immunotyping (serum and urine), and carbohydrate deficient transferrin (Photo courtesy of Sebia)
Image: The Capillarys 3 TERA is an automated analyzer based on capillary zone electrophoresis and UV detection for the quantitative analysis of Hba1c, proteins (serum and urine), immunotyping (serum and urine), and carbohydrate deficient transferrin (Photo courtesy of Sebia)
The electrophoresis of serum proteins remains a laboratory cornerstone for the diagnosis and monitoring of patients with plasma cell disorders, such as monoclonal gammopathy of undetermined significance, multiple myeloma, Waldenström macroglobulinemia, and AL amyloidosis.

Gel electrophoresis remains the method used by most clinical laboratories in the USA. However usage of gel electrophoresis is gradually decreasing while that of capillary electrophoresis is increasing. More recently, analysis of liquid media by capillary electrophoresis was developed and applied to the analysis of serum proteins for clinical purposes.

Laboratory Immunologists at The Johns Hopkins School of Medicine (Baltimore, MD, USA) tested all serum samples analyzed by the immunology laboratory over the course of eight days for routine clinical purposes during the months of October and November 2019, totaling 304 sera. There were 160 females (62 ± 16 years, range 19 -95) and 144 males (65 ± 14 years, range 23-97), with no significant difference in age according to sex.

Sera were first ran using the system currently in use, which consists of a thin-layer agarose gel, HYDRAGEL 30 Protein (E) (Sebia, Lisses, France) and the Sebia Hydrasys 2 semi-automated analyzer. Sera were then assayed on the Sebia Capillarys III TERA automated analyzer using CAPI 3 Protein (E) reagents. Serum immunofixation electrophoresis (SIFE) was performed in 214 of the total 304 sera because already ordered by the provider for most cases. Sera were pre-diluted according to the immunoglobulin G, A, and M concentrations, and then ran on the immunofixation system currently in use, which consists of a thin-layer agarose gel (HYDRAGEL IF 2/4, from Sebia) and the Hydrasys 2 semi-automated analyzer.

The scientists reported that Gel and capillary estimated the concentration of albumin, gamma region, and M-spikes nearly perfectly, and that of beta, alpha-2, and alpha-1 regions with excellent correlation. The two systems classified concordantly 268 of 304 sera (88% agreement) as having no, one, or two M-spikes, but differed in the remaining 36 sera (12%). Gel electrophoresis correctly identified M-spikes in 82 of 112 sera that were shown to have monoclonal band(s) by immunofixation (73% sensitivity), and correctly did not reveal M-spikes in 97/102 sera that had no immunofixation bands (95% specificity). Capillary achieved slightly higher sensitivity (85/112, 76%) and slightly lower specificity (94/102, 92%), but the two areas under the ROC curves were nearly identical at 0.84.

The authors concluded that Gel and capillary electrophoresis systems perform similarly to estimate the concentration of serum protein fractions and detect M-spikes. The Capillarys system has the disadvantages of a higher equipment cost and requiring a greater sample volume. On the other hand, Capillarys requires less involvement of laboratory technicians, offers a faster turn-around time, identifies the specimens they are being analyzed, does not depend upon the chemicals needed to stain and destain the gels, and is more amenable to remote reporting. The study was published on April 29, 2021 in the journal Practical Laboratory Medicine.

Related Links:
The Johns Hopkins School of Medicine
Sebia


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.